Comparison between early and late allocation groups
| Early (n = 76)median (IR: Q1–Q3) | Late (n = 77)median (IR: Q1–Q3) | ||
|---|---|---|---|
| HADS, Hospital Anxiety and Depression Scale; H&Y (on), Hoehn and Yahr stages during on; H&Y II/III/IV, Hoehn and Yahr stages II, II, IV during on; IR, interquartile range; M/F, male/female; MMSE, Mini Mental State Examination; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale part I, II, III, IV and total score. | |||
| *Expressed as number of patients and p value based on χ2 test. | |||
| Demography | |||
| M/F* | 48/28 | 40/37 | 0.16 |
| Age | 67.5 (61.5–72) | 69 (62.5–73) | 0.7 |
| PD characteristics | |||
| Disease duration | 7 (4–11) | 8 (4–12) | 0.59 |
| H&Y (on) | 2.5 (2.5–3) | 3 (2.5–3) | 0.56 |
| H&Y II/III/IV* | 39/29/8 | 32/35/10 | 0.48 |
| Freezers/non-freezers* | 31/45 | 32/45 | 0.92 |
| Clinical data | |||
| UPDRS-total (on) | 54 (46–65.5) | 56 (49–63) | 0.62 |
| UPDRS I (on) | 4 (2–5) | 3 (2–4) | 0.1 |
| UPDRS II (on) | 16 (12–19.5) | 16 (12–20) | 0.67 |
| UPDRS III (on) | 31 (25–37) | 34 (28–41) | 0.32 |
| UPDRS IV (on) | 3 (1–5) | 2 (1–5) | 0.43 |
| Levodopa (mg) | 500 (300–700) | 350 (200–550) | 0.07 |
| MMSE | 28.5 (27–30) | 29 (27–30) | 0.99 |
| Brixton | 4 (2–6) | 4.0 (2–6) | 0.45 |
| HADS anxiety | 6.5 (4–10) | 6 (4–10) | 0.97 |
| HADS depression | 7.5 (5–10) | 6 (4.5–9) | 0.45 |